Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.40 |
| ▸ | FEN1 | P39748 | 7/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723509 | 0.92 | FEN1 (0.40) | KMOTGFBR1PTGS2FEN1ALOX5AP | |
| SCHEMBL6718600 | 0.90 | GLO1 (0.42) | KMOTGFBR1PTGS2FEN1ALOX5AP | |
| SCHEMBL6721414 | 0.90 | KMO (0.48) | KMOTGFBR1PTGS2FEN1ALOX5AP | |
| SCHEMBL6723308 | 0.90 | KMO (0.39) | KMOTGFBR1PTGS2FEN1ALOX5AP | |
| SCHEMBL6730013 | 0.88 | PTGS2 (0.43) | KMOTGFBR1PTGS2FEN1ALOX5AP | |
| SCHEMBL6722770 | 0.88 | KMO (0.38) | KMOTGFBR1PTGS2FEN1ALOX5AP | |
| SCHEMBL6721827 | 0.88 | PDE3B (0.41) | KMOTGFBR1PTGS2FEN1ALOX5AP | |
| SCHEMBL6722015 | 0.88 | FEN1 (0.37) | KMOTGFBR1PTGS2FEN1ALOX5AP | |
| SCHEMBL6721590 | 0.88 | KMO (0.43) | KMOTGFBR1PTGS2FEN1ALOX5AP | |
| SCHEMBL6723029 | 0.87 | PTGS2 (0.41) | KMOTGFBR1PTGS2FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | KMO 675/4885TGFBR1 1568/4885PTGS2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.